Literature DB >> 31506382

Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.

Jonathan Fisher1,2, Roshan Sharma2,3, Dilu Wisidagamage Don1, Marta Barisa1, Marina Olle Hurtado1, Pierre Abramowski1, Lucy Porter1, William Day4, Roberto Borea1, Sarah Inglott5, John Anderson6,4, Dana Pe'er7,8.   

Abstract

Despite the benefits of chimeric antigen receptor (CAR)-T cell therapies against lymphoid malignancies, responses in solid tumors have been more limited and off-target toxicities have been more marked. Among the possible design limitations of CAR-T cells for cancer are unwanted tonic (antigen-independent) signaling and off-target activation. Efforts to overcome these hurdles have been blunted by a lack of mechanistic understanding. Here, we showed that single-cell analysis with time course mass cytometry provided a rapid means of assessing CAR-T cell activation. We compared signal transduction in expanded T cells to that in T cells transduced to express second-generation CARs and found that cell expansion enhanced the response to stimulation. However, expansion also induced tonic signaling and reduced network plasticity, which were associated with expression of the T cell exhaustion markers PD-1 and TIM-3. Because this was most evident in pathways downstream of CD3ζ, we performed similar analyses on γδT cells that expressed chimeric costimulatory receptors (CCRs) lacking CD3ζ but containing DAP10 stimulatory domains. These CCR-γδT cells did not exhibit tonic signaling but were efficiently activated and mounted cytotoxic responses in the presence of CCR-specific stimuli or cognate leukemic cells. Single-cell signaling analysis enabled detailed characterization of CAR-T and CCR-T cell activation to better understand their functional activities. Furthermore, we demonstrated that CCR-γδT cells may offer the potential to avoid on-target, off-tumor toxicity and allo-reactivity in the context of myeloid malignancies.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31506382      PMCID: PMC7055420          DOI: 10.1126/scisignal.aax1872

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  59 in total

1.  On the use of the Kolmogorov-Smirnov statistical test for immunofluorescence histogram comparison.

Authors:  F Lampariello
Journal:  Cytometry       Date:  2000-03-01

2.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Xiaojun Qian; Ajay K Gopal; David G Maloney; Catherine G Lindgren; Yukang Lin; John M Pagel; Lihua E Budde; Andrew Raubitschek; Stephen J Forman; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

3.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.

Authors:  Alexander I Salter; Richard G Ivey; Jacob J Kennedy; Valentin Voillet; Anusha Rajan; Eva J Alderman; Uliana J Voytovich; Chenwei Lin; Daniel Sommermeyer; Lingfeng Liu; Jeffrey R Whiteaker; Raphael Gottardo; Amanda G Paulovich; Stanley R Riddell
Journal:  Sci Signal       Date:  2018-08-21       Impact factor: 8.192

5.  Systems biology. Conditional density-based analysis of T cell signaling in single-cell data.

Authors:  Smita Krishnaswamy; Matthew H Spitzer; Michael Mingueneau; Sean C Bendall; Oren Litvin; Erica Stone; Dana Pe'er; Garry P Nolan
Journal:  Science       Date:  2014-10-23       Impact factor: 47.728

6.  The key to unlocking CARs.

Authors: 
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 54.908

7.  Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.

Authors:  R Asslan; A Pradines; C Pratx; C Allal; G Favre; F Le Gaillard
Journal:  Biochem Biophys Res Commun       Date:  1999-07-14       Impact factor: 3.575

8.  NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.

Authors:  Daniel D Billadeau; Jadee L Upshaw; Renee A Schoon; Christopher J Dick; Paul J Leibson
Journal:  Nat Immunol       Date:  2003-05-11       Impact factor: 25.606

9.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

10.  Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.

Authors:  Hans-Jürgen Gober; Magdalena Kistowska; Lena Angman; Paul Jenö; Lucia Mori; Gennaro De Libero
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  8 in total

1.  High-dimensional functional phenotyping of preclinical human CAR T cells using mass cytometry.

Authors:  Ilaria M Michelozzi; Jahangir Sufi; Thomas A Adejumo; Persis J Amrolia; Christopher J Tape; Alice Giustacchini
Journal:  STAR Protoc       Date:  2022-02-09

2.  A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy.

Authors:  Gabrielle M Ferry; Charles Agbuduwe; Megan Forrester; Sophie Dunlop; Kerry Chester; Jonathan Fisher; John Anderson; Marta Barisa
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

Review 3.  Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.

Authors:  Satyen H Gohil; J Bryan Iorgulescu; David A Braun; Derin B Keskin; Kenneth J Livak
Journal:  Nat Rev Clin Oncol       Date:  2020-12-04       Impact factor: 66.675

Review 4.  γδ T Cells: The Ideal Tool for Cancer Immunotherapy.

Authors:  Mahboubeh Yazdanifar; Giulia Barbarito; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

Review 5.  Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Authors:  Fabio Morandi; Mahboubeh Yazdanifar; Claudia Cocco; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-07-22       Impact factor: 6.600

Review 6.  Chimeric Antigen Receptor beyond CAR-T Cells.

Authors:  Vicky Mengfei Qin; Criselle D'Souza; Paul J Neeson; Joe Jiang Zhu
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

7.  Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.

Authors:  Kevin P Nishimoto; Taylor Barca; Aruna Azameera; Amani Makkouk; Jason M Romero; Lu Bai; Mary M Brodey; Jackie Kennedy-Wilde; Hui Shao; Stephanie Papaioannou; Amy Doan; Cynthia Masri; Ngoc T Hoang; Hayden Tessman; Vidhya Dhevi Ramanathan; Ana Giner-Rubio; Frank Delfino; Kriti Sharma; Kevin Bray; Matthew Hoopes; Daulet Satpayev; Ranjita Sengupta; Marissa Herrman; Stewart E Abbot; Blake T Aftab; Zili An; Swapna Panuganti; Sandra M Hayes
Journal:  Clin Transl Immunology       Date:  2022-02-02

8.  γδ T cell costimulatory ligands in antitumor immunity.

Authors:  Joseph M McGraw; Deborah A Witherden
Journal:  Explor Immunol       Date:  2022-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.